Pacira BioSciences (PCRX) News
NASDAQ: PCRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.31-0.08 (-0.22%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PCRX news summary
We found 7 recent headlines mentioning Pacira BioSciences (PCRX): 7 in the past week and 7 in the past 30 days, most often from Nasdaq, Seeking Alpha, PR Newswire. For price context, PCRX is down 0.22% at $36.31. The most recent story, "JP Morgan Upgrades Pacira BioSciences to Neutral from Underweight", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pacira BioSciences headlines
- JP Morgan Upgrades Pacira BioSciences to Neutral from UnderweightFintel reports that on October 8, 2026, JP Morgan upgraded their outlook for Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) from Underweight to Neutral.Pacira BioSciences, Inc., based in the United…Nasdaq
- Pacira BioSciences jumps 44% on Viatris acquisition dealSeeking AlphaPCRX, VTRS
- PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.PCRX shareholders will receive just $36.50 per share in cash, representing an aggregate equity value of $1.65 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and…PR Newswire
- Why Pacira BioSciences Skyrocketed TodayKey PointsPacira BioSciences is being bought out by Viatrias.NasdaqPCRX, VTRS
- Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal; Shares FlyViatris pledged Thursday to buy small biotech company Pacira Biosciences for $1.65 billion, sending Pacira stock skyrocketing. The post Pacira Biosciences Snags $1.65 Billion Viatris Takeover Deal;…Investor's Business DailyPCRX, VTRS
- Viatris to buy Pacira BioSciences for $36.50/share in cashSeeking AlphaPCRX, VTRS
- Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain TherapiesAdds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International…PR NewswirePCRX, VTRS